| Literature DB >> 32260204 |
Ambre Dezaire1,2, Christophe H Marchand3,4, Marine Vallet2, Nathalie Ferrand1, Soraya Chaouch2,5, Elisabeth Mouray2, Annette K Larsen1, Michèle Sabbah1, Stéphane D Lemaire3, Soizic Prado2, Alexandre E Escargueil1.
Abstract
High-throughput screening assays have been designed to identify compounds capable of inhibiting phenotypes involved in cancer aggressiveness. However, most studies used commercially available chemical libraries. This prompted us to explore natural products isolated from marine-derived fungi as a new source of molecules. In this study, we established a chemical library from 99 strains corresponding to 45 molecular operational taxonomic units and evaluated their anticancer activity against the MCF7 epithelial cancer cell line and its invasive stem cell-like MCF7-Sh-WISP2 counterpart. We identified the marine fungal Paradendryphiella salina PC 362H strain, isolated from the brown alga Pelvetia caniculata (PC), as one of the most promising fungi which produce active compounds. Further chemical and biological characterizations of the culture of the Paradendryphiella salina PC 362H strain identified (-)-hyalodendrin as the active secondary metabolite responsible for the cytotoxic activity of the crude extract. The antitumor activity of (-)-hyalodendrin was not only limited to the MCF7 cell lines, but also prominent on cancer cells with invasive phenotypes including colorectal cancer cells resistant to chemotherapy. Further investigations showed that treatment of MCF7-Sh-WISP2 cells with (-)-hyalodendrin induced changes in the phosphorylation status of p53 and altered expression of HSP60, HSP70 and PRAS40 proteins. Altogether, our study reveals that this uninvestigated marine fungal crude extract possesses a strong therapeutic potential against tumor cells with aggressive phenotypes and confirms that members of the epidithiodioxopiperazines are interesting fungal toxins with anticancer activities.Entities:
Keywords: anticancer agent; epidithiodioxopiperazines; marine-derived fungi; resistant phenotypes; secondary metabolites
Mesh:
Substances:
Year: 2020 PMID: 32260204 PMCID: PMC7230232 DOI: 10.3390/md18040191
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Evaluation of 138 crude extracts on MCF7-Sh-WISP2 cell viability. (A) Crude extracts were tested on MCF7-Sh-WISP2 cells and categorized as follows: non-active (IC50 ≥ 50 µg/mL); moderately active (5 < IC50 < 50 µg/mL) and very active (IC50 ≤ 5 µg/mL). IC50 values were calculated as the mean of two individual experiments done in duplicate. (B) The activity ratios of crude extracts on MCF7-Sh-WISP2 (Sh) over 3T3-F442A pre-adipocytes (PA) cell viability were calculated and were categorized as follows: mostly active on pre-adipocytes ([IC50 (Sh)/IC50 (PA)] ≥ 1); equally active on MCF7-Sh-WISP2 cells and pre-adipocytes (1 < [IC50 (Sh)/IC50 (PA)] < 2); mostly active on MCF7-Sh-WISP2 cells ([IC50 (Sh)/IC50 (PA)] ≤ 2). Among the 138 crude extracts tested, the IC50 (Sh)/IC50 (PA) ratios could not be determined for 13 of them because of out-of-range IC50 values for either pre-adipocytes or MCF7-Sh-WISP2 cells.
The most active strains for which one of the crude extracts has an IC50 value lower than 5 µg/mL toward MCF7-Sh-WISP2 cells. Crude extracts were assessed on cell viability using the methylthiazolyldiphenyl-tetrazolium bromide (MTT) assay. Results are expressed as means of two individual experiments.
| IC50 (µg/mL) | IC50 (µg/mL) | |||||||
|---|---|---|---|---|---|---|---|---|
| Strain Code | Culture Medium | MCF7 | MCF7-Sh- | 3T3-F442A | Culture Medium | MCF7 | MCF7-Sh- | 3T3-F442A |
| LD150F | MEA–ASW | 0.3 | 2.7 | 6.3 | Tubaki | 2.4 | 3.4 | 36.8 |
| AN325T | 1.5 | 0.4 | 3.7 | 1.8 | 1.2 | 3.8 | ||
| LD327H | 0.9 | 0.3 | 0.7 | 0.5 | 0.1 | 0.1 | ||
| SL332T | 4.2 | 3.0 | 3.3 | 61.0 | 111.2 | 50.7 | ||
| PC362H | 0.4 | 0.2 | 0.5 | 8.3 | 10.0 | 16.7 | ||
| SL469T | 88.2 | 22.8 | 37.6 | 2.3 | 2.8 | 4.7 | ||
| LD481H | 0.3 | 0.4 | 0.3 | 0.3 | 0.9 | 0.2 | ||
Figure 2The structures of 1–4.
1H and 13C NMR data of 1 (DMSO-d6, 600 MHz and 150 MHz, 298K).
| Pos. | δC, Type | δH
| Pos. | δC, Type | δH
|
|---|---|---|---|---|---|
|
| 35.4, CH2 | (α) 1.14, m; (β) 1.60, m |
| 30.7, CH2 | (α) 1.09, m; (β) 1.58, m |
|
| 27.6, CH2 | 1.47, m |
| 25.9, CH2 | (α) 1.54, m, (β) 1.80, m |
|
| 76.7, CH | 2.99, dt (10.7, 5.1) |
| 48.1, CH | 1.91, m |
|
| 38.6, C | - |
| 9.7, CH3 | 0.59, s |
|
| 50.0, CH | 0.93,d (1.9) |
| 18.9, CH3 | 0.91, s |
|
| 17.8, CH2 | (β) * 1.40, m; (α) * 1.63, m |
| 41.3, CH | 2.36, m |
|
| 25.6, CH2 | 1.95, m |
| 19.0, CH3 | 1.21, d (6.6) |
|
| 132.8, C | - |
| 178.9, C | - |
|
| 135.8, C | - |
| 28.1, CH3 | 0.89, s |
|
| 36.3, C | - |
| 15.8, CH3 | 0.69, s |
|
| 33.6, CH2 | (α) 2.38, m; (β) 1.68, m |
| 23.7, CH3 | 0.84, s |
|
| 69.8, CH | 3.87, brt (7.5) |
| - | 4.31, d (5.1) |
|
| 48.3, C | - |
| - | 4.42, br s |
|
| 51.6, C | - |
Broad singlet (br s); interchangeable (*); broad signal (br).
Figure 3Key HMBC and COSY correlations in 1.
Evaluation of 1–4 on cell viability of MCF7, MCF7-Sh-WISP2 and 3T3-F442A cells. Results are shown as three individual experiments done in duplicate ± SD.
| Cell Line | IC50 µg/mL (µM) | ||||
|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | Hydroxi | |
| MCF7 | 20 µg/mL | > 25 µg/mL | 0.07 µg/mL | 15 µg/mL | 8.8 µM |
| MCF7-Sh-WISP2 | > 25 µg/mL | > 25 µg/mL | 0.046 µg/mL | 24 µg/mL | 11.6 µM |
| 3T3-F442A | > 25 µg/mL | > 25 µg/mL | 0.099 µg/mL | 92 µg/mL | 14.5 µM |
Figure 4Intracellular signaling pathways modulated in MCF7-Sh-WISP2 cells exposed to 3. (A) MCF7-Sh-WISP2 cells were treated or not with 2.8 µM of 3 for 48 h. The cells were lysed and the protein extracts were subjected to a protein array analysis. The table chart on the right of the blot indicates the individual proteins tested here. Results are representative of two individual experiments. (B) MCF7-Sh-WISP2 cells were treated or not with 2.4 µM of 3 for 72 h. The cells were then lysed and the antigens revealed by immunolabelling using antibodies directed against p53, phospho-p53 (Serine 15), PRAS40 and phospho-PRAS40 (Threonine 246). β-Actin immunoblot served as a loading control. (C) Western blots from three independent experiments were quantified by densitometry and values expressed as (phospho-p53/total p53) or (phospho-PRAS40/total PRAS40) ratios. The statistical analysis of experimental data was performed using Student’s paired t-test comparing the hyalodendrin-treated samples with the vehicle control. Results are expressed as means ± standard deviation (SD), * p < 0.05.
Figure 5Expression of cell stress-related proteins in MCF7-Sh-WISP2 cells exposed to 3. (A) MCF7-Sh-WISP2 cells were treated or untreated with 5.7 µM of 3 for 48 h. The cells were lysed and the protein extracts were subjected to a protein array analysis. The table chart on the right of the blot indicates the individual proteins tested here. (B) MCF7-Sh-WISP2 cells were treated or untreated with 2.4 µM of 3 for 72 h. The cells were then lysed and the antigens revealed by immunolabelling using antibodies directed against p53, phospho-p53 (Serine 46), BAX and β-actin.
Figure 6The in vitro reduction in 3 by the thioredoxin system. Compound 3, dissolved in acetonitrile (ACN), was incubated in the presence of the NADPH thioredoxin reductase (Trr1) alone and in the presence of the whole thioredoxin system (Trr1+Trx1). NADPH consumptions were followed spectrophotometrically and compared to those obtained in control experiments (ACN alone). Results are expressed as means ± standard deviation (SD) and significance was evaluated by Student’s t-test (** p < 0.01).
Figure 7Extracted ion chromatograms of 3 (left) at m/z 325.0681 [M + H]+ and diacetamide conjugated 3 (right) at m/z 441.1268 [M + H]+ resulting from the in vitro alkylation of 3 in the presence of Trx system after addition of iodoacetamide at two different incubation times. (A) 3 without Trx system, (B) 3 in the presence of Trx system and quenched with iodoacetamide at 6 min, (C) 3 in the presence of Trx system and quenched with iodoacetamide at 25 min, (D) Trx system alone.
Cytotoxic activity of 3 on a panel of cancer and non-tumorigenic cell lines. Results are shown as three individual experiments done in duplicate ± SD. Not determined (ND).
| Cell line | IC50 (nM) | Phenotypes | Relevant Genetic Status | MSS vs MSI | |
|---|---|---|---|---|---|
| Breast | MC7-Sh-WISP2 | 142.0 ± 3.0 | mesenchymal, invasive | ER-/PR-/HER2- | |
| MCF7 | 216.3 ± 6.0 | epithelial | ER+/PR+/HER2-, TP53 WT | ||
| MDA-MB-231 | 132.5 ± 13.4 | mesenchymal, invasive | ER-/PR-/HER2-, TP53 mutant (R280K) | ||
| Colon | SW48 | 149.0 ± 15.5 | mesenchymal, invasive | BRAF and KRAS WT, TP53 mutant (R248Y) | MSI |
| DLD1 | 40.0 ± 5.8 | epithelial | KRAS mutant (G13D), TP53 mutant (S241F) | MSI | |
| HT29 | 58.0 ± 13.7 | epithelial | BRAF mutant (V600E), TP53 mutant (R273H) | MSS | |
| HT29 5FU | 146.8 ± 10.2 | mesenchymal, invasive | ND | MSS | |
| HT29 oxa | 141.8 ± 2.6 | epithelial | ND | MSS | |
| HT29 SN-38 | 93.8 ± 13.6 | epithelial | ND | MSS | |
| HCT116 | 48.0 ± 9.3 | epithelial | KRAS mutant (G13D), TP53 WT | MSI | |
| HCT116 5FU | 72.0 ± 10.9 | mesenchymal, invasive | ND | MSI | |
| HCT116 oxa | 25.7 ± 4.2 | mesenchymal, invasive | ND | MSI | |
| HCT116 SN-38 | 43.8 ± 4.2 | mesenchymal, invasive | ND | MSI | |
| LS513 | 78.0 ± 9.3 | epithelial | KRAS mutant (G12D), TP53 WT | MSS | |
| LOVO | 73.4 ± 16.4 | epithelial | KRAS mutant (G13D; A14V), TP53 WT | MSI | |
| RKO | 74.3 ± 1.9 | mesenchymal, invasive | BRAF mutant (V600E), TP53 WT | MSI | |
| LS174T | 158.0 ± 13.0 | epithelial | KRAS mutant (G12D), TP53 WT | MSI | |
| SW480 | 163.7 ± 11.0 | mesenchymal, invasive | KRAS mutant (G12V), TP53 mutant (R273H) | MSS | |
| Cervix | HeLa | 69.0 ± 9.9 | epithelial | TP53 WT (HPV positive) | |
| Normal | 3T3F442A | 305.0 ± 4.2 | pre-adipocytic | ||
| C19 | 252.5 ± 20.5 | fibroblastic |